

Tumor Board Case Summary

Patient name: Cornelius Samwa **Patient ID:** SYN238 **DOB:** 6 Decemer 1959
Tumor Board Date: 14 April 2025
Presenter: Dr. K. Sharma, MD, EGFR-Mutant Lung Cancer Expert Panel

Case Overview

Patient: lifelong non-smoker
Diagnosis: EGFR L858R-positive lung adenocarcinoma with pleural dissemination
PD-L1 TPS: <1%
Date of Diagnosis: 27 August 2021
Therapy Initiated: Osimertinib 80 mg QD (17 September 2021)
Duration of Therapy: ongoing

Initial Presentation & Diagnostic Workup

- Symptoms: Worsening dyspnea, dull chest pain, 2.5 kg weight loss
- CT (Aug 2021): RUL mass 5.3 cm, nodular pleural thickening, trace effusion
- Thoracentesis: Adenocarcinoma cells, TTF-1+, CK7+, Napsin A+
- Biopsy: Micropapillary-predominant adenocarcinoma, Ki-67 40%
- Molecular:
 - EGFR L858R (Exon 21)
 - No T790M, ALK, MET, KRAS, or HER2
 - PD-L1: 0%, TMB 3.0/Mb
- Baseline MRI brain: No metastasis

Imaging & Labs Summary

Latest Imaging (March 2025):

- CT Chest:**
 - RUL mass: 1.7 cm (was 5.3 cm at diagnosis)
 - Pleura: No new nodularity or effusion
- PET-CT:** No new uptake; prior sites metabolically inactive
- MRI Brain:** Normal
- Labs (April 2025):**

Test	Value	Normal Range
Hemoglobin	11.4 g/dL	13.5–17.5 g/dL
WBC	6.8 ×10 ⁹ /L	4–11 ×10 ⁹ /L
Platelets	182 ×10 ⁹ /L	150–400 ×10 ⁹ /L
Creatinine	0.94 mg/dL	0.6–1.3 mg/dL

Test	Value	Normal Range
ALT/AST	24 / 28 U/L	<40 / <40 U/L
EGFR plasma ctDNA	Negative	—

Clinical Issues

- Osimertinib well tolerated: managed paronychia, mild anemia, and dry cough
 - ECOG 1, walks 3 km daily
 - No CNS involvement to date
 - Plasma NGS negative for resistance mutations (T790M, C797S, MET ampl.)
-

Panel Recommendation

- **Continue Osimertinib**
 - Monitor cardiac function (QTc stable at 465 ms)
 - Re-image Q3 months
 - If resistance develops, rebiopsy for tissue NGS
 - Consider 2L planning: Amivantamab, Lazertinib, or combination trials
 - Patient is a strong candidate for eventual clinical trial participation
-

Approved by Tumor Board: Yes

Follow-up Plan: Next review in 6 months or upon progression

Chair, Molecular Tumor Board:

Dr. K. Sharma, MD

Thoracic Oncology & Molecular Therapeutics
